Understanding KEYTRUDA (pembrolizumab): A Multi-Purpose Brea

1. Introduction: A New Approach to Fighting Cancer

KEYTRUDA (pembrolizumab) represents a paradigm shift in oncology. Unlike traditional chemotherapy, which works by directly attacking rapidly dividing cells, KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody. It is a form of immunotherapy designed to help your own immune system detect and fight cancer cells. By releasing the biological "brakes" that cancer uses to evade the body’s defenses, KEYTRUDA enables a powerful, targeted immune response against several types of advanced cancers.

2. How It Works: Unmasking Cancer Cells

To understand how KEYTRUDA works, it helps to visualize the interaction between your immune system’s T cells and cancer cells as a "lock and key" mechanism.

The Lock: Your T cells have a receptor called PD-1. This acts as a lock that, when turned, tells the T cell to remain inactive so it doesn't attack healthy tissue.
The Keys: Some cancer cells produce proteins called . These act as keys that fit into the PD-1 lock.

Cancer Type	Patient Criteria/Context
Melanoma	Patients with melanoma that cannot be removed by surgery (unresectable) or has spread (metastatic).
Non-Small Cell Lung Cancer (NSCLC)	• First-line (Single Agent): For metastatic tumors with high PD-L1 expression (TPS ≥50%) and no EGFR or ALK genetic markers (your doctor must test for these aberrations first). • First-line (Combination): Used with pemetrexed and carboplatin specifically for metastatic nonsquamous NSCLC. • Previously Treated: For tumors expressing PD-L1 (TPS ≥1%) that progressed after platinum-containing chemotherapy.
Head and Neck Squamous Cell Cancer (HNSCC)	Patients with recurrent or metastatic disease that progressed on or after platinum-containing chemotherapy.
Classical Hodgkin Lymphoma (cHL)	Adult and pediatric patients with refractory disease, or those whose cancer returned after three or more prior lines of therapy.
Urothelial Carcinoma	• Patients ineligible for cisplatin-containing chemotherapy. • Patients whose cancer progressed during/after platinum-containing chemotherapy, or within 12 months of receiving such chemotherapy before or after surgery (neoadjuvant or adjuvant treatment).
MSI-H Cancers	Adult and pediatric patients with unresectable or metastatic solid tumors identified as Microsatellite Instability-High (MSI-H) that have progressed after prior treatment with no alternative options.*

Understanding KEYTRUDA (pembrolizumab): A Multi-Purpose Breakthrough in Cancer Immunotherapy

1. Introduction: A New Approach to Fighting Cancer

2. How It Works: Unmasking Cancer Cells

3. Treatable Conditions: Who Can Benefit?

4. The Patient Experience: Dosage and Administration

5. Safety First: Common and Serious Side Effects

6. Important Considerations for Specific Groups

7. Conclusion: Empowering the Patient Journey